MSnet.org

gather and share multiple sclerosis information

Submit your story     l     about featured merchants     l     contact us    

Search MSnet

   

Insert keyword(s), then press enter. 

advanced search

Home

What is MS?

MS Symptoms
MS Webcasts

Stories

Support

MSlog.com

Catalog

join email list


Lymphoma Living with Lymphoma

Making Cancer Treatment Decisions


Author:

Brian Stabler, PhD

University of North Carolina School of Medicine

Medically Reviewed On: March 31, 2006

Introduction

I was sitting, half dressed on an examining table, feeling a bit wobbly and staring balefully at my oncologist. He was trying to talk me out of a decision I had just announced. “Look, Brian,” he said, “you don’t need a bone marrow transplant. We can manage your disease with chemotherapy.” He was emphatic. “But this feels right for me,” I said. “Don’t you see?” He would not accede the point. “This transplant idea would be like taking a sledge hammer to crack a walnut,” he said. “It’s too much. Too risky. Let’s keep our powder dry for the time being, OK?” As it turned out, it was not exactly “OK” with me. My mind was made up. I eventually went to the Dana Farber Cancer Institute in Boston to have what was then called a “front-end” autologous bone marrow transplant.

The goal of a bone marrow transplant (BMT) is to replace a patient’s abnormal bone marrow cells with healthy ones. This is accomplished by destroying a patient’s bone marrow with full-body radiation or ultra high-dose chemotherapy and then injecting healthy bone marrow cells from either a donor (allogeneic transplantor cells from the patient himself (autologous transplant). In my case, I donated my own bone marrow, which was then chemically "purged" to get rid of cancer cells and later given back to me as part of the transplant procedure. A “front-end” procedure means that the transplantation is done at the outset of the therapy regimen rather than at a later point when one’s disease has relapsed. Typically, a BMT is done only after all other treatment methods have failed.

I had my BMT in 1990, when doing an autologous transplant as an initial treatment for low-grade lymphoma was still considered experimental. The idea was that if the transplant was performed early on, there was, theoretically, a better chance of a cure, or at least a substantial remission. I am not sure why I was so determined to follow this more risky, unorthodox course.  I had a very close and trusting relationship with my oncologist, and up to that point he had made most of the treatment decisions for my lymphoma. I just felt that a transplant had to be done, sooner or later, and I knew in my heart that it had to be then.
 

A Personal History

Page 1 of 5 Next Page >>

 

 

© Copyright  MSnet 2001. All rights reserved. Read our disclaimer.